OIPE



2

ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/071,779

DATE: 03/01/2002

TIME: 10:58:04

Input Set : A:\EP.txt

2 <110> APPLICANT: Achilefu, Samuel I.

Output Set: N:\CRF3\03012002\J071779.raw

```
3
              Rajagopalan, Raghavan
      4
              Dorshow, Richard B.
      5
              Bugaj, Joseph E.
              Mallinckrodt Inc.
      9 <120> TITLE OF INVENTION: Dye-Bioconjugates for Simultaneous Optical Diagnostic and
              Therapeutic Applications
     10
     12 <130> FILE REFERENCE: MRD-75
C--> 14 <140> CURRENT APPLICATION NUMBER: US/10/071,779
     15 <141> CURRENT FILING DATE: 2002-02-07
     17 <160> NUMBER OF SEQ ID NOS: 8
     19 <170> SOFTWARE: PatentIn Version 3.1
     21 <210> SEQ ID NO: 1
     22 <211> LENGTH: 8
     23 <212> TYPE: PRT
     24 <213> ORGANISM: Artificial Sequence
     26 <220> FEATURE:
W--> 27 <221> NAME/KEY: MOD RES
     28 <222> LOCATION: (1)...(8)
     29 <223> OTHER INFORMATION: Xaa at location 1 represents D-Phe. Artificial sequence is
              completely synthesized.
     31 <223> OTHER INFORMATION: Xaa at locations 2 and 7 represents Cys with an
              intramolecular disulfide bond between two Cys
              amino acids. Artificial sequence is completely synthesized.
     34 <223> OTHER INFORMATION: Xaa at location 4 represents D-Trp. Artificial sequence is
              completely synthesized.
     37 <400> SEQUENCE: 1
W-->38
        Xaa Xaa Tyr Xaa Lys Thr Xaa Thr
     39
          1
     42 <210> SEQ ID NO: 2
     43 <211> LENGTH: 8
     44 <212> TYPE: PRT
     45 <213> ORGANISM: Artificial Sequence
     47 <220> FEATURE:
W--> 48 <221> NAME/KEY: MOD RES
     49 <222> LOCATION: (1)...(8)
     50 <223> OTHER INFORMATION: Xaa at location 1 represents D-Phe. Artificial sequence is
              completely synthesized.
     52 <223> OTHER INFORMATION: Xaa at locations 2 and 7 represents Cys with an
     53
              intramolecular disulfide bond between two Cys
              amino acids. Artificial sequence is completely synthesized.
     55 <223> OTHER INFORMATION: Xaa at location 4 represents D-Trp. Artificial sequence is
```

completely synthesized.

56

DATE: 03/01/2002

TIME: 10:58:04

Input Set : A:\EP.txt Output Set: N:\CRF3\03012002\J071779.raw 57 <223> OTHER INFORMATION: Xaa at location 8 represents Thr-OH. Artificial sequence is 58 completely synthesized. 60 <400> SEQUENCE: 2 W--> 61 Xaa Xaa Tyr Xaa Lys Thr Xaa Xaa 62 65 <210> SEQ ID NO: 3 66 <211> LENGTH: 11 67 <212> TYPE: PRT 68 <213> ORGANISM: Unknown 70 <220> FEATURE: W--> 71 <221> NAME/KEY: MOD RES 72 <222> LOCATION: (1)...(11) 73 <223> OTHER INFORMATION: Bombesin analog 75 <400> SEQUENCE: 3 76 Gly Ser Gly Gln Trp Ala Val Gly His Leu Met 77 1 5 80 <210> SEQ ID NO: 4 81 <211> LENGTH: 11 82 <212> TYPE: PRT 83 <213> ORGANISM: Unknown 85 <220> FEATURE: W--> 86 <221> NAME/KEY: MOD RES 87 <222> LOCATION: (1)...(11) 88 <223> OTHER INFORMATION: Bombesin analog 90 <400> SEQUENCE: 4 91 Gly Asp Gly Gln Trp Ala Val Gly His Leu Met 5 1 95 <210> SEQ ID NO: 5 96 <211> LENGTH: 8 97 <212> TYPE: PRT 98 <213> ORGANISM: Unknown 100 <220> FEATURE: W--> 101 <221> NAME/KEY: MOD RES 102 <222> LOCATION: (1)...(8) 103 <223> OTHER INFORMATION: Cholecystokinin octapeptide analogs 105 <400> SEQUENCE: 5 106 Asp Tyr Met Gly Trp Met Asp Phe 107 1 110 <210> SEQ ID NO: 6 111 <211> LENGTH: 8 '112 <212> TYPE: PRT 113 <213> ORGANISM: Artificial Sequence 115 <220> FEATURE: W--> 116 <221> NAME/KEY: MOD RES 117 <222> LOCATION: (1)...(8) 118 <223> OTHER INFORMATION: Xaa at locations 3 and 6 represents Norleucine. Artificial

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/071,779

121 <400> SEQUENCE: 6

W--> 122 Asp Tyr Xaa Gly Trp Xaa Asp Phe

sequence is completely synthesized.

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/071,779

DATE: 03/01/2002 TIME: 10:58:04

Input Set : A:\EP.txt

Output Set: N:\CRF3\03012002\J071779.raw

123 1 128 <210> SEQ ID NO: 7 129 <211> LENGTH: 8 130 <212> TYPE: PRT 131 <213> ORGANISM: Artificial Sequence 133 <220> FEATURE: W--> 134 <221> NAME/KEY: MOD RES 135 <222> LOCATION: (1)...(8) 136 <223> OTHER INFORMATION: Xaa at location 1 represents D-Asp. Artificial sequence is completely synthesized. 138 <223> OTHER INFORMATION: Xaa at locations 3 and 6 represents Norleucine. Artificial sequence is completely synthesized. 141 <400> SEQUENCE: 7 W--> 142 Xaa Tyr Xaa Gly Trp Xaa Asp Phe 143 1 146 <210> SEQ ID NO: 8 147 <211> LENGTH: 8 148 <212> TYPE: PRT 149 <213> ORGANISM: Artificial Sequence 151 <220> FEATURE: W--> 152 <221> NAME/KEY: MOD RES 153 <222> LOCATION: (1)...(8) 154 <223> OTHER INFORMATION: Xaa at location 1 represents D-Lys. Artificial sequence is completely synthesized.

3/1/02

157 <400> SEQUENCE: 8

159

W--> 158 Xaa Pro Arg Arg Pro Tyr Ile Leu

5

3/1/02





 VERIFICATION SUMMARY
 DATE: 03/01/2002

 PATENT APPLICATION: US/10/071,779
 TIME: 10:58:05

Input Set : A:\EP.txt

Output Set: N:\CRF3\03012002\J071779.raw

L:14 M:270 C: Current Application Number differs, Replaced Application Number
L:27 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:38 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:48 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2
L:61 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:71 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3
L:86 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
L:101 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
L:116 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
L:122 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:134 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:7
L:142 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:152 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:8
L:158 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8